In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome

Gut

Volumn 65, Issue 10, 2016, Pages 1733-1743

  Todt, Daniel ^b   Gisa, Anett ^a   Radonic, Aleksandar ^c   Nitsche, Andreas ^c   Behrendt, Patrick ^a,b   Suneetha, Pothakamuri Venkata ^a   Pischke, Sven ^a,d   Bremer, Birgit ^a   Brown, Richard J P ^b   Manns, Michael P ^a,e   Cornberg, Markus ^a,e   Thomas Bock, C ^c   Steinmann, Eike ^b   Wedemeyer, Heiner ^a,e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e German Center for Infectious Diesease (DZIF)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CHRONIC HEPATITIS E; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GENETIC HETEROGENEITY; GENETIC VARIATION; HEPATITIS E; HEPATITIS E VIRUS; HEPATITIS E VIRUS GENOTYPE 3C; HEPATITIS E VIRUS GENOTYPE 3E; HEPATITIS E VIRUS GENOTYPE 3F; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MUTAGENESIS; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION; CHRONIC DISEASE; DRUG EFFECTS; DRUG MONITORING; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG MONITORING; FEMALE; GENETIC HETEROGENEITY; GENOME, VIRAL; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS; RIBAVIRIN;

EID: 84973364294     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-311000     Document Type: Article

References (37)

1. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology 2012;142:1388-97.e1.
2. Holla RP, Ahmad I, Ahmad Z, et al. Molecular virology of hepatitis E virus. Semin Liver Dis 2013;33:3-14.
3. Meng XJ. Hepatitis E virus: animal reservoirs and zoonotic risk. Vet Microbiol 2010;140:256-65.
4. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012;379:2477-88.
5. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-17.
6. Behrendt P, Steinmann E, Manns MP, et al. The impact of hepatitis E in the liver transplant setting. J Hepatol 2014;61:1418-29.
7. Lauring AS, Frydman J, Andino R. The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol 2013;11:327-36.
8. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 2010;6:e1001005.
9. Duggal NK, Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 2012;12:687-95.
10. Lhomme S, Abravanel F, Dubois M, et al. Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J Virol 2012;86:10006-14.
11. Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012;55:695-708.
12. Dalton HR, Kamar N, Izopet J. Hepatitis E in developed countries: current status and future perspectives. Future Microbiol 2014;9:1361-72.
13. Kamar N, Abravanel F, Lhomme S, et al. Hepatitis E virus: chronic infection, extra-hepatic manifestations, and treatment. Clin Res Hepatol Gastroenterol 2015;39:20-7.
14. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-20.
15. Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 2013;33:722-6.
16. Pischke S, Stiefel P, Franz B, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant 2012;12:3128-33.
17. Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 2014;147:1008-11.e7; quiz e15-6.
18. Debing Y, Emerson SU, Wang Y, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother 2014;58:267-73.
19. Anderson JP, Daifuku R, Loeb LA. Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 2004;58:183-205.
20. Eigen M. The origin of genetic information: viruses as models. Gene 1993;135:37-47.
21. Beaucourt S, Vignuzzi M. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol 2014;8:10-15.
22. Shukla P, Nguyen HT, Faulk K, et al. Adaptation of a genotype 3 hepatitis E virus t efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J Virol 2012;86:5697-707.
23. Shukla P, Nguyen HT, Torian U, et al. Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci USA 2011;108:2438-43.
24. Todt D, François C, Anggakusuma, et al Antiviral activity of different interferon types and sub types against hepatitis E virus replication. Antimicrob Agents Chemother 2016;60:2132-9.
25. Drave SA, Debing Y, Walter S, et al. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. J Viral Hepat Published Online First: 19 Feb 2016. doi: 10.1111/jvh.12515
26. Vignuzzi M, Stone JK, Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res 2005;107:173-81.
27. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-9.
28. Lanford RE, Chavez D, Guerra B, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001;75:8074-81.
29. Sierra M, Airaksinen A, Gonzalez-Lopez C, et al. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 2007;81:2012-24.
30. Chung DH, Sun Y, Parker WB, et al. Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J Virol 2007;81:11722-9.
31. Young KC, Lindsay KL, Lee KJ, et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003;38:869-78.
32. Hofmann WP, Polta A, Herrmann E, et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007;132:921-30.
33. Lutchman G, Danehower S, Song BC, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007;132:1757-66.
34. Chevaliez S, Brillet R, Lazaro E, et al. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007;81:7732-41.
35. Dietz J, Schelhorn SE, Fitting D, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 2013;87:6172-81.
36. Zhou X, Wang Y, Metselaar HJ, et al. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. J Hepatol 2014;61:746-54.
37. Wang Y, Zhou X, Debing Y, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 2014;146:1775-83.